09.09.2013 10:14

EMA (Evropská léková agentura) oznámila následující:

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) started a new review procedure for bromocriptine-containing medicines when used orally for preventing or suppressing lactation (milk production) in women following childbirth. The PRAC will assess whether the benefits of these medicines outweigh the risk of rare but potentially serious (including fatal) cardiovascular, neurological and psychiatric side effects.

Převzato a více informací na